Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | PPARD | Q03181 | 6/20 | 0.44 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7256359 | 0.95 | LMNA (0.58) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL25928800 | 0.92 | TSHR (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL21318205 | 0.92 | TSHR (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL21318214 | 0.92 | TSHR (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL14519724 | 0.92 | TSHR (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL21422305 | 0.92 | TSHR (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL21422304 | 0.92 | TSHR (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL21422313 | 0.92 | TSHR (0.60) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL5021516 | 0.89 | FAAH (0.40) | SLC22A6LMNATSHRALDH1A1MEN1 | |
| SCHEMBL409946 | 0.83 | EGLN1 (0.53) | SLC22A6LMNATSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230233526-A1 | GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-07-27 | — | — | US | disclosed |
| CN-113150068-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | Prism BioLab Co., Ltd. (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9969772-B2 | Covalent granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9969770-B2 | Proline compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9849112-B2 | Pyrrole compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-12-26 | — | — | US | disclosed |
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-7851439-B2 | EFTU inhibitors or aminothiazoles and their uses | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| CN-101801186-A | Natural bioactive compounds | AQUAPHARM BIO DISCOVERY LTD | 2010-08-11 | — | — | CN | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| EP-0233413-B1 | 3-(2-AMINOETHYL)INDOLE AND -INDOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 1993-05-05 | — | — | EP | disclosed |
| US-4980368-A | CEREBRALVASCULAR DISORDERS; ANTIHYPOXIA AGENTS; COGNITION ACTIVATORS; SENILITY | BEECHAM-WUELFING GMBH & CO. KG (DE) | 1990-12-25 | — | — | US | disclosed |
| EP-0233413-A2 | 3-(2-Aminoethyl)indole and -indoline derivatives, processes for their preparation and pharmaceutical compositions containing them | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218014-A1 | AZAINDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, DNASE1L3, DNASE1 | SLC22A6 3496/4885LMNA 128/4885TSHR 4232/4885 |
| US-20080221142-A1 | useful in interfering with the life cycle of bacteria and in treating or preventing a bacterial infection | LPO, PCNA, BPGM | SLC22A6 2155/4885LMNA 1077/4885TSHR 3775/4885 |
| US-20170015707-A1 | COVALENT GRANZYME B INHIBITORS | GZMB, CTSB, DNASE1L3 | SLC22A6 2623/4885LMNA 73/4885TSHR 3769/4885 |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | SLC22A6 1095/4885LMNA 3843/4885TSHR 3335/4885 |
| US-20230233526-A1 | GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING | GZMB, SERPINB1, CTSB | SLC22A6 2319/4885LMNA 162/4885TSHR 4811/4885 |
| US-10017522-B2 | Alpha helix mimetics and methods relating thereto | PLOD3, COL1A1, THPO | SLC22A6 3861/4885LMNA 255/4885TSHR 3526/4885 |
| US-20170015706-A1 | PROLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, CTSB, RNPEP | SLC22A6 1194/4885LMNA 194/4885TSHR 4338/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | SLC22A6 3029/4885LMNA 4484/4885TSHR 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.